Patient dosing underway in phase 2 trial of DME candidate
Click Here to Manage Email Alerts
Key takeaways:
- The phase 2 VERONA clinical trial is investigating EYP-1901 for the treatment of diabetic macular edema.
- EyePoint expects topline data from the trial in 2025.
The first patient has been dosed in a phase 2 clinical trial investigating EYP-1901 for the treatment of diabetic macular edema, according to a press release from EyePoint Pharmaceuticals.
The company expects to enroll approximately 25 patients in the randomized, controlled, single-masked VERONA trial. Patients will receive one of two intravitreal doses of EYP-1901, an investigational sustained delivery therapy containing vorolanib, or aflibercept control.
Image: Adobe Stock
The primary efficacy endpoint is the time to first supplemental aflibercept injection up to 24 weeks. Secondary endpoints will assess safety, change in best corrected visual acuity, change in central subfield thickness and change in Diabetic Retinopathy Severity Scale.
“Dosing the first patient in the phase 2 VERONA trial represents another significant milestone in advancing our mission to improve the lives of patients with serious retinal diseases,” Jay S. Duker, MD, CEO of EyePoint, said in the release. “We are encouraged by the growing body of clinical data for EYP-1901, and we are optimistic that EYP-1901 has the potential to change the current treatment paradigm for DME with topline data expected in Q1 2025.”
Read more about
Click Here to Manage Email Alerts